Provided by Tiger Trade Technology Pte. Ltd.

Avis Budget

125.21
-1.2400-0.98%
Post-market: 125.19-0.0200-0.02%19:52 EST
Volume:403.25K
Turnover:50.97M
Market Cap:4.41B
PE:-2.10
High:130.52
Open:127.65
Low:124.96
Close:126.45
52wk High:212.81
52wk Low:54.03
Shares:35.20M
Float Shares:14.77M
Volume Ratio:0.80
T/O Rate:2.73%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-59.6591
EPS(LYR):-51.2958
ROE:5800.00%
ROA:1.69%
PB:-1.84
PE(LYR):-2.44

Loading ...

Arovella Files IND for Lead CAR-iNKT Therapy as Cash Reserves Back 2026 Clinical Push

TIPRANKS
·
3 hours ago

Tempest Therapeutics: Strategic Pivot to Dual‑Target CAR‑T Platform Extends Runway and Resets Investment Thesis to Buy

TIPRANKS
·
Yesterday

WeShop Enters Into Retail Partnerships Ahead of Winter Travel Season

MT Newswires Live
·
Jan 21

KPMG and Alpaca Vietnam Form Strategic Alliance to Deploy Basel III Solutions in Compliance with Circular No. 14/2025/TT-NHNN

prnewswire
·
Jan 21

Avis Budget Group Inc. to Announce Fourth Quarter 2025 Results and Host Investor Call

Reuters
·
Jan 16

AdAlta outlines “East to West” strategy and first-in-class CAR-T program

TIPRANKS
·
Jan 15

Positioning Arcellx for a Pivotal 2026: Anito-cel’s Differentiated Safety, Best-in-Class CAR T Launch Potential, and Undervalued Entry Point

TIPRANKS
·
Jan 14

Will Dispatch Bio CAR T Solid Tumor Trial Shift CARsgen Therapeutics' (SEHK:2171) Narrative?

Simply Wall St.
·
Jan 14

AdAlta Schedules Investor Webinar on CAR-T Deal and ‘East to West’ Strategy

TIPRANKS
·
Jan 13

Kyverna Therapeutics: Strong Early Autoimmune CAR-T Data, Accelerated SPS Timeline, and Solid Cash Runway Support Buy Rating

TIPRANKS
·
Jan 13

AdAlta Secures A$1.2m Placement to Accelerate ‘East to West’ CAR-T Strategy

TIPRANKS
·
Jan 13

CRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2026 Milestones

GlobeNewswire
·
Jan 12

Kyverna Therapeutics Provides Corporate Update and Outlines 2026 Strategic Priorities at the J.P. Morgan Healthcare Conference

GlobeNewswire
·
Jan 12

BioNTech Provides Strategic Business Update and Outlines 2026 Areas of Focus at 44th Annual J.P. Morgan Healthcare Conference

GlobeNewswire
·
Jan 12

Cartesian Therapeutics Highlights Recent Progress and Outlines 2026 Outlook

GlobeNewswire
·
Jan 09

Citi Sticks to Their Buy Rating for CAR Group (WN6)

TIPRANKS
·
Jan 09

Is CAR Group Limited (ASX:CAR) Potentially Undervalued?

Simply Wall St.
·
Jan 09

Allogene outlines 2026 as program-defining year for allogeneic CAR T

TIPRANKS
·
Jan 08

Allogene Therapeutics Positions 2026 as a Program-Defining Year for Scalable, Real-World Allogeneic CAR T

GlobeNewswire
·
Jan 08

WiseTech, REA and CAR Look Best Insulated From AI Threat -- Market Talk

Dow Jones
·
Jan 07